Loading clinical trials...
Loading clinical trials...
Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival
Conditions
Interventions
Propranolol and etodolac
Placebo
Locations
6
Israel
HaEmek Medical Center
Afula, Israel
Rambam Health Care Campus
Haifa, Israel
Rabin Medical Center
Petah Tikva, Israel
Sourasky Medical Center
Tel Aviv, Israel
Sheba Medical Center
Tel Litwinsky, Israel
Asaf Harofeh Medical Center
Ẕerifin, Israel
Start Date
February 28, 2019
Primary Completion Date
February 28, 2027
Completion Date
February 28, 2027
Last Updated
April 18, 2019
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Assaf-Harofeh Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions